Publication Name	World Journal of Hepatology
Manuscript ID	85497
Country	United States

Received	2023-04-30 15:04
Peer-Review Started	2023-04-30 15:06
To Make the First Decision
Return for Revision	2023-06-07 22:22
Revised	2023-06-18 20:40
Second Decision	2023-08-07 02:53
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-08-07 08:22
Articles in Press	2023-08-07 08:22
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-08-17 00:11
Publish the Manuscript Online	2023-08-22 07:39

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Systematic Reviews
Article Title	Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
Manuscript Source	Invited Manuscript
All Author List	Jasmine Tidwell, Natalie Balassiano, Anjiya Shaikh and Mahmoud Nassar
Funding Agency and Grant Number
Corresponding Author	Mahmoud Nassar, MD, MSc, PhD, Doctor, Doctor, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, WNY 705 Maple Road, Williamsville, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Key Words	Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Cyclophilin inhibitors; Fibroblast growth factor 21 analogs; Dual peroxisome proliferator-activated receptor agonists; Pan peroxisome proliferator-activated receptor agonists
Core Tip	Non-alcoholic fatty liver disease (NAFLD) has become a significant global health issue. There is no medication approved by the Federal Drug Administration for the treatment of NAFLD. However, there are several therapeutic classes currently being studied in clinical trials. In this systematic review, we analyze the scientific data of cyclophilin inhibitors, fibroblast growth factor 21 analogs, and dual and pan peroxisome proliferator-activated receptor agonists for the treatment of NAFLD.
Publish Date	2023-08-22 07:39
Citation	Tidwell J, Balassiano N, Shaikh A, Nassar M. Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review. World J Hepatol 2023; 15(8): 1001-1012
URL	https://www.wjgnet.com/1948-5182/full/v15/i8/1001.htm
DOI	https://dx.doi.org/10.4254/wjh.v15.i8.1001

Full Article (PDF)	WJH-15-1001-with-cover.pdf
Full Article (Word)	WJH-15-1001.docx
PRISMA 2009 Checklist	85497-PRISMA-2009-Checklist-revision.docx
Manuscript File	85497_Auto_Edited-JLW.docx
Answering Reviewers	85497-Answering reviewers.pdf
Audio Core Tip	85497-Audio core tip.mp3
Biostatistics Review Certificate	85497-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	85497-Conflict-of-interest statement.pdf
Copyright License Agreement	85497-Copyright license agreement.pdf
Peer-review Report	85497-Peer-review(s).pdf
Scientific Misconduct Check	85497-Bing-Fan JR-2.png
Scientific Editor Work List	85497-Scientific editor work list.pdf
CrossCheck Report	85497-CrossCheck report.pdf
CrossCheck Report	85497-CrossCheck.png